Published in Gastroenterology on June 01, 1981
Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels. World J Gastroenterol (2005) 1.05
Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis. J Clin Invest (1988) 0.94
Morphologic and biochemical changes in dogs after portacaval shunt plus bile fistula or ileal bypass: failure of bile fistula or ileal bypass to prevent hepatocyte atrophy. Hepatology (1983) 0.80
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. Eur Respir J (2004) 2.40
Propranolol--a medical treatment for portal hypertension? Lancet (1980) 2.27
Early administration of vapreotide for variceal bleeding in patients with cirrhosis. N Engl J Med (2001) 2.25
Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 2.06
Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology (1980) 2.02
Ectopic varices in portal hypertension. Clin Gastroenterol (1985) 1.90
Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology (1988) 1.79
Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future. J Hepatol (2000) 1.78
Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72
Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut (2002) 1.68
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J Hepatol (2001) 1.54
Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology (1991) 1.52
Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet (1987) 1.52
Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis. Gastroenterology (1994) 1.50
Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet (1981) 1.47
The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology (1982) 1.44
Pulmonary vascular disorders in portal hypertension. Eur Respir J (1998) 1.44
Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology (1982) 1.43
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transpl Surg (1999) 1.41
Clearance of atrial natriuretic peptide in patients with cirrhosis. Role of liver failure. J Hepatol (1991) 1.39
Hemodynamic, neurohumoral, and metabolic responses to amino acid infusion in patients with cirrhosis. Gastroenterology (1992) 1.39
Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology (1997) 1.33
Percutaneous cannulation of the internal jugular vein in patients with coagulopathies: an experience based on 1,000 attempts. Anesthesiology (1982) 1.28
Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med (2001) 1.23
Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol (1999) 1.19
Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis. Gut (1986) 1.19
Portal hypertension in systemic mastocytosis. Gastroenterology (1978) 1.17
Idiopathic portal hypertension (perisinusoidal fibrosis) after renal transplantation. Gut (1979) 1.15
Portal hypertension in fulminant viral hepatitis. Gut (1980) 1.12
Persistence of systemic and splanchnic hyperkinetic circulation in liver transplant patients. Hepatology (1993) 1.12
Chronic cholestatic diseases. J Hepatol (2000) 1.11
Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol (1998) 1.11
Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology (1978) 1.10
Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int (2005) 1.10
Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis. Hepatology (1982) 1.09
Pulmonary hypertension complicating portal hypertension. Am Rev Respir Dis (1979) 1.07
Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. Gut (1978) 1.07
Effect of propranolol on hepatic blood flow in normal and portal hypertensive rats. Clin Sci (Lond) (1982) 1.06
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology (2000) 1.06
Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology (1990) 1.05
Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat. Gastroenterology (1992) 1.05
Postprandial hemodynamic responses in patients with cirrhosis. Hepatology (1988) 1.04
Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol (2000) 1.04
Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol (1994) 1.03
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology (1985) 1.03
Hemodynamic effects of endotoxin and platelet activating factor in cirrhotic rats. Gastroenterology (1992) 1.01
Hemodynamic effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology (1987) 1.00
Hepatic sarcoidosis with portal hypertension. A report of seven cases with a review of the literature. Q J Med (1987) 1.00
Transvenous (transjugular) liver biopsy. An experience based on 100 biopsies. Am J Dig Dis (1978) 0.99
Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol (1986) 0.99
Liver adenoma and focal nodular hyperplasia in a man with high endogenous sex steroids. Gastroenterology (1987) 0.99
Hypoxemia in patients with cirrhosis: relationship with liver failure and hemodynamic alterations. J Hepatol (1997) 0.98
Hemodynamic changes in patients with portal venous obstruction. Hepatology (1983) 0.98
Serum hyaluronan as a marker of liver fibrosis. J Hepatol (1995) 0.97
Changes in splanchnic blood flow in portal hypertensive rats. Eur J Clin Invest (1982) 0.97
Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology (1999) 0.95
The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol (1995) 0.95
Portal vein thrombosis and fatal pulmonary thromboembolism associated with oral contraceptive treatment. J Clin Gastroenterol (1981) 0.94
Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children. Pharmacol Ther (1995) 0.94
Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features. J Hepatol (1994) 0.94
Reduction of intrahepatic vascular space in the pathogenesis of portal hypertension. In vitro and in vivo studies in the rat. Gastroenterology (1987) 0.94
Hepatic blood flow in humans during isoflurane-N2O and halothane-N2O anesthesia. Anesth Analg (1990) 0.94
Effects of lipopolysaccharide on TNF-alpha production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol (2000) 0.93
HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation (2000) 0.93
Portal hypertension and ascites in acute hepatitis: clinical, hemodynamic and histological correlations. Hepatology (1989) 0.92
Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology (1990) 0.92
Glucagon selectively increases splanchnic blood flow in patients with well-compensated cirrhosis. Hepatology (1988) 0.92
Endothelial calcium-calmodulin dependent nitric oxide synthase in the in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol (1997) 0.91
[Fulminant hepatitis: an experience based on 137 cases. I. Complications (author's transl)]. Gastroenterol Clin Biol (1977) 0.91
Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology (1999) 0.91
Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology (1997) 0.90
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology (1987) 0.90
[Tienilic acid-induced hepatitis associated with liver/kidney microsomal antibody (author's transl)]. Nouv Presse Med (1980) 0.89
Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology (1999) 0.89
Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens (1986) 0.89
Biochemical evidence that Na+,K+-ATPase is located at the lateral region of the hepatocyte surface membrane. FEBS Lett (1979) 0.89
[Complications of portal hypertension: a consensus]. Rev Mal Respir (2004) 0.89
Altered control of vascular tone by adenosine triphosphate-sensitive potassium channels in rats with cirrhosis. Gastroenterology (1994) 0.89
Failure of haemodynamic measurements to predict recurrent gastrointestinal bleeding in cirrhotic patients receiving propranolol. J Hepatol (1987) 0.89
Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology (1997) 0.88
Acute haemodynamic responses and inhibition of tumour necrosis factor-alpha by pentoxifylline in rats with cirrhosis. Clin Sci (Lond) (1996) 0.88
Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology (1998) 0.88
Validation of transit-time ultrasound flow probes to directly measure portal blood flow in conscious rats. Am J Physiol (1996) 0.87
Effect of propranolol on hepatic blood flow in patients with cirrhosis. Clin Pharmacol Ther (1985) 0.87
Hemodynamic effects of dobutamine in patients with alcoholic cirrhosis. Clin Pharmacol Ther (1983) 0.87
[Encephalopathy in acute hepatic atrophy. Effect of the purification of middle molecules. Preliminary results]. Nouv Presse Med (1975) 0.87
Discrepancy between wedged hepatic venous pressure and portal venous pressure after acute propranolol administration in patients with alcoholic cirrhosis. Gastroenterology (1984) 0.87
Blood and plasma 5-hydroxytryptamine levels in patients with cirrhosis. Hepatology (1994) 0.87
Alterations in isoprenaline sensitivity in patients with cirrhosis: evidence of abnormality of the sympathetic nervous activity. Br J Clin Pharmacol (1986) 0.87
Ischemic hepatitis due to obstructive sleep apnea. Gastroenterology (1995) 0.86
Gastrointestinal bleeding due to chronic portal vein thrombosis in ulcerative colitis. Dig Dis Sci (1979) 0.86
Blunted natriuresis and abnormal systemic hemodynamic responses to C-type and brain natriuretic peptides in rats with cirrhosis. J Hepatol (1995) 0.86
Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hypertension. Gastroenterology (2000) 0.86
Acute effects of captopril on systemic and renal hemodynamics and on renal function in cirrhotic patients with ascites. Gastroenterology (1985) 0.86